Real world embedding
close
프로필 배경
프로필 로고

Real world embedding

  • 분류 전체보기 (422)
    • devOps (5)
    • Pharmacology (411)
      • News (8)
      • BS (402)
  • 홈
  • BS
  • devOps

Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital

Orchard Therapeutics has raised $34 million in new capital from the second closing of a securities purchase agreement, extending its cash runway through to mid-2025. The funding will support the advancement of its hematopoietic stem cell (HSC) gene therapy portfolio and preparations for the US launch of OTL-200 for MLD, pending FDA approval. The company expects that this funding will provide imp..

  • format_list_bulleted BS
  • · 2023. 6. 27.
  • textsms

NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering

NRx Pharmaceuticals has announced the completion of its registered direct offering for 9,670,002 shares of common stock at $0.65 per share, resulting in gross proceeds of approximately $6.28 million before deducting placement agent fees and other expenses. The company intends to use net proceeds from the offering for working capital and general corporate purposes, as well as potentially using it..

  • format_list_bulleted BS
  • · 2023. 6. 11.
  • textsms
  • navigate_before
  • 1
  • navigate_next
공지사항
  • 데이터 요청 관련 문의
전체 카테고리
  • 분류 전체보기 (422)
    • devOps (5)
    • Pharmacology (411)
      • News (8)
      • BS (402)
최근 글
인기 글
최근 댓글
태그
  • #Study
  • #Clinical Trial
  • #astrazeneca
  • #Trial
  • #FDA approval
  • #Safety
  • #fda
  • #cancer
  • #N/A
  • #Phase 3
전체 방문자
오늘
어제
전체
Copyright © 쭈미로운 생활 All rights reserved.
Designed by JJuum

티스토리툴바

개인정보

  • 티스토리 홈
  • 포럼
  • 로그인

단축키

내 블로그

내 블로그 - 관리자 홈 전환
Q
Q
새 글 쓰기
W
W

블로그 게시글

글 수정 (권한 있는 경우)
E
E
댓글 영역으로 이동
C
C

모든 영역

이 페이지의 URL 복사
S
S
맨 위로 이동
T
T
티스토리 홈 이동
H
H
단축키 안내
Shift + /
⇧ + /

* 단축키는 한글/영문 대소문자로 이용 가능하며, 티스토리 기본 도메인에서만 동작합니다.